

Table 1.1.E-1.1: Key Safety and Efficacy Variables for All Eyes Treated

Preoperative MRSE	1 Month		3 Months		6 Months		9 Months		12 Months	
	N									
	168		156		80		18		7	
	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%
<b>EFFICACY VARIABLES</b>										
UCVA 20/20 or better	55	32.7	53	34.0	24	30.0	6	33.3	2	28.6
UCVA 20/25 to 20/40	81	48.2	76	48.7	41	51.3	8	44.4	5	71.4
UCVA 20/40 or better (cumulative)	136	81.0	129	82.7	65	81.3	14	77.8	7	100.0
MRSE $\pm$ 0.50 D	85	50.6	91	58.3	39	48.8	8	44.4	3	42.9
MRSE $\pm$ 1.00 D	45	26.8	28	17.9	21	26.3	5	27.8	1	14.3
MRSE $\pm$ 2.00 D	26	15.5	26	16.7	16	20.0	4	22.2	3	42.9
Eyes Without Monovision										
# Non-Monovision (N)	101		95		41		12		6	
UCVA 20/20 or better	40	39.6	41	43.2	17	41.5	5	41.7	2	33.3
UCVA 20/25 to 20/40	44	43.6	44	46.3	19	46.3	6	50.0	4	66.7
UCVA 20/40 or better (cumulative)	84	83.2	85	89.5	36	87.8	11	91.7	6	100.0
<b>SAFETY VARIABLES</b>										
Loss of > 2 lines BSCVA	4	2.4	0	0.0	1	1.3	0	0.0	0	0.0
BSCVA worse than 20/40	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0
Increase > 2 D cylinder	2	1.2	0	0.0	0	0.0	0	0.0	0	0.0
BSCVA worse than 20/25 if 20/20 or better preop	8	4.8	5	3.2	2	2.5	3	16.7	0	0.0